AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Lipocine's LPCN 2101 for Epilepsy Shows Promise at AES Annual Meeting
ByAinvest
Tuesday, Aug 26, 2025 8:05 am ET1min read
Lipocine Inc. announced that two abstracts related to LPCN 2101, a potential epilepsy treatment, have been accepted for poster presentation at the 2025 American Epilepsy Society annual meeting. LPCN 2101 is in development for the treatment of epilepsy and has shown promise in clinical trials. The presentation will cover the oral toxicokinetics and clinical pharmacokinetics of the medication, as well as its tolerability. The meeting will be held in Atlanta, Georgia, from December 5-9.
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in innovative oral delivery technologies, has announced that two abstracts related to its epilepsy treatment candidate, LPCN 2101, have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting. The meeting will be held in Atlanta, Georgia, from December 5 to December 9 [1].The abstracts, titled "Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive Steroid (NAS) Anti-seizure Medication (ASM) Candidate for Women with Epilepsy (WWE)" and "Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating (PAM) Candidate for Epilepsy," will be presented by a team of researchers [1].
LPCN 2101 is in development for the potential treatment of epilepsy and has shown promise in clinical trials. The presentations will cover the oral toxicokinetics and clinical pharmacokinetics of the medication, as well as its tolerability. The abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025 [1].
Lipocine's proprietary technology platform enables the development of products with effective oral delivery, targeting large addressable markets with significant unmet medical needs. The company's clinical development candidates include LPCN 1154, oral brexanolone for postpartum depression, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor, among others [1].
Eli Lilly, a competitor in the oral GLP-1 pill market, has also recently announced promising data from its Phase 3 trial for an oral GLP-1 pill, which could help people with obesity and Type 2 diabetes lose significant weight [2].
References:
[1] https://www.marketscreener.com/news/lipocine-announces-lpcn-2101-abstracts-accepted-for-presentation-at-aes-2025-ce7c50d9d880f022
[2] https://abcnews.go.com/GMA/Wellness/eli-lillys-oral-glp-1-pill-people-type/story?id=124963525
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet